LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

Search

Medpace Holdings Inc

Gesloten

SectorGezondheidszorg

310.35 -1.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

305.58

Max

314.49

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.4M

115M

Verkoop

22M

559M

K/W

Sectorgemiddelde

23.931

56.602

EPS

3.67

Winstmarge

20.516

Werknemers

5,900

EBITDA

-4.9M

120M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+1.52% upside

Dividenden

By Dow Jones

Volgende Winsten

21 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

61M

9B

Vorige openingsprijs

311.38

Vorige sluitingsprijs

310.35

Nieuwssentiment

By Acuity

50%

50%

209 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Medpace Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2025, 23:20 UTC

Winsten

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 mei 2025, 23:48 UTC

Marktinformatie

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 mei 2025, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 mei 2025, 23:24 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

13 mei 2025, 23:24 UTC

Marktinformatie
Winsten

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 mei 2025, 22:58 UTC

Winsten

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mei 2025, 22:58 UTC

Winsten

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mei 2025, 22:58 UTC

Winsten

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 mei 2025, 22:58 UTC

Winsten

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 mei 2025, 22:38 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 mei 2025, 22:38 UTC

Winsten

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 mei 2025, 22:37 UTC

Winsten

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 mei 2025, 22:36 UTC

Winsten

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 mei 2025, 22:35 UTC

Winsten

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 mei 2025, 22:34 UTC

Winsten

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 mei 2025, 22:33 UTC

Winsten

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 mei 2025, 22:33 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 mei 2025, 22:33 UTC

Winsten

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 mei 2025, 22:30 UTC

Winsten

Aristocrat Interim Dividend 44 Australian Cents/Share

13 mei 2025, 22:30 UTC

Winsten

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 mei 2025, 22:29 UTC

Winsten

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 mei 2025, 22:28 UTC

Winsten

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 mei 2025, 21:15 UTC

Winsten

Nu Holdings 1Q Rev $3.2B >NU

13 mei 2025, 21:03 UTC

Top Nieuws

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 mei 2025, 20:32 UTC

Winsten

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mei 2025, 20:31 UTC

Winsten

Alcon 1Q Sales $2.45B >ALC.EB

13 mei 2025, 20:30 UTC

Winsten

Alcon 1Q Rev $2.47B >ALC.EB

13 mei 2025, 20:30 UTC

Winsten

Alcon 1Q EPS 70c >ALC.EB

Peer Vergelijking

Prijswijziging

Medpace Holdings Inc Prognose

Koersdoel

By TipRanks

1.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 318.5 USD  1.52%

Hoogste 355 USD

Laagste 285 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Medpace Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

7 ratings

1

Buy

6

Hold

0

Sell

Technische score

By Trading Central

300 / 302.88Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

209 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.